Andreas Karas

835 total citations
16 papers, 320 citations indexed

About

Andreas Karas is a scholar working on Infectious Diseases, Epidemiology and Surgery. According to data from OpenAlex, Andreas Karas has authored 16 papers receiving a total of 320 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Infectious Diseases, 8 papers in Epidemiology and 3 papers in Surgery. Recurrent topics in Andreas Karas's work include Clostridium difficile and Clostridium perfringens research (8 papers), Microscopic Colitis (6 papers) and Antibiotic Resistance in Bacteria (3 papers). Andreas Karas is often cited by papers focused on Clostridium difficile and Clostridium perfringens research (8 papers), Microscopic Colitis (6 papers) and Antibiotic Resistance in Bacteria (3 papers). Andreas Karas collaborates with scholars based in United Kingdom, Switzerland and Germany. Andreas Karas's co-authors include Oliver A. Cornely, Gbenga Kazeem, Benoît Guéry, Maria J. G. T. Vehreschild, Christopher Longshaw, José Palacios, José María Aguado, Karen Bisnauthsing, Francesco Menichetti and Veli-Jukka Anttila and has published in prestigious journals such as Clinical Infectious Diseases, The Lancet Infectious Diseases and Journal of Antimicrobial Chemotherapy.

In The Last Decade

Andreas Karas

15 papers receiving 319 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andreas Karas United Kingdom 8 261 208 83 44 39 16 320
Sofie M. van Dorp Netherlands 9 337 1.3× 195 0.9× 53 0.6× 79 1.8× 52 1.3× 12 370
Kristin Nagaro United States 9 388 1.5× 279 1.3× 81 1.0× 52 1.2× 51 1.3× 13 434
Ana Álvarez‐Uría Spain 11 282 1.1× 200 1.0× 27 0.3× 23 0.5× 52 1.3× 20 364
Tracey Roberts United States 5 305 1.2× 198 1.0× 28 0.3× 63 1.4× 96 2.5× 5 343
Linda Ward Canada 8 318 1.2× 199 1.0× 77 0.9× 105 2.4× 28 0.7× 12 384
Rebecca Perlmutter United States 9 267 1.0× 210 1.0× 69 0.8× 33 0.8× 67 1.7× 19 311
Courtney Jones United States 11 254 1.0× 122 0.6× 69 0.8× 189 4.3× 23 0.6× 28 373
Paolo Carfagna Italy 11 219 0.8× 181 0.9× 46 0.6× 33 0.8× 31 0.8× 24 331
Minerva Galang United States 3 533 2.0× 418 2.0× 128 1.5× 27 0.6× 78 2.0× 3 591
Jeanne Couturier France 10 250 1.0× 149 0.7× 52 0.6× 56 1.3× 47 1.2× 34 323

Countries citing papers authored by Andreas Karas

Since Specialization
Citations

This map shows the geographic impact of Andreas Karas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas Karas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas Karas more than expected).

Fields of papers citing papers by Andreas Karas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andreas Karas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas Karas. The network helps show where Andreas Karas may publish in the future.

Co-authorship network of co-authors of Andreas Karas

This figure shows the co-authorship network connecting the top 25 collaborators of Andreas Karas. A scholar is included among the top collaborators of Andreas Karas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andreas Karas. Andreas Karas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Shastri, Priya, et al.. (2025). Coccidioidomycosis in Europe: a systematic literature review of epidemiology, treatment and outcomes. Journal of Antimicrobial Chemotherapy. 81(1).
2.
Torre‐Cisneros, Julián, et al.. (2025). Cefiderocol treatment for patients infected by Stenotrophomonas maltophilia, Burkholderia cepacia complex and Achromobacter spp.: subgroup analysis from the PERSEUS study. European Journal of Clinical Microbiology & Infectious Diseases. 44(6). 1367–1374. 3 indexed citations
3.
Torre‐Cisneros, Julián, Benito Almirante, Carmen Martos, et al.. (2025). Effectiveness and safety of cefiderocol treatment in patients with Gram-negative bacterial infections in Spain in the early access programme: results of the PERSEUS study. European Journal of Clinical Microbiology & Infectious Diseases. 44(6). 1375–1390. 7 indexed citations
4.
5.
Guéry, Benoît, Andreas Karas, Gbenga Kazeem, et al.. (2020). Pharmacokinetic analysis of an extended-pulsed fidaxomicin regimen for the treatment of Clostridioides (Clostridium) difficile infection in patients aged 60 years and older in the EXTEND randomized controlled trial. Journal of Antimicrobial Chemotherapy. 75(4). 1014–1018. 4 indexed citations
6.
Cornely, Oliver A., et al.. (2019). Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection: EXTEND study subgroup analyses. European Journal of Clinical Microbiology & Infectious Diseases. 38(6). 1187–1194. 16 indexed citations
7.
Wilcox, Mark H., Oliver A. Cornely, Benoît Guéry, et al.. (2019). Microbiological Characterization and Clinical Outcomes After Extended-Pulsed Fidaxomicin Treatment for Clostridioides difficile Infection in the EXTEND Study. Open Forum Infectious Diseases. 6(11). ofz436–ofz436. 2 indexed citations
8.
9.
Högenauer, Christoph, Yashwant R. Mahida, Andreas Stallmach, et al.. (2018). Pharmacokinetics and safety of fidaxomicin in patients with inflammatory bowel disease and Clostridium difficile infection: an open-label Phase IIIb/IV study (PROFILE). Journal of Antimicrobial Chemotherapy. 73(12). 3430–3441. 10 indexed citations
10.
Guéry, Benoît, Francesco Menichetti, Veli-Jukka Anttila, et al.. (2017). Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial. The Lancet Infectious Diseases. 18(3). 296–307. 143 indexed citations
11.
Jamrozy, Dorota, Francesc Coll, Alison E. Mather, et al.. (2017). Evolution of mobile genetic element composition in an epidemic methicillin-resistant Staphylococcus aureus: temporal changes correlated with frequent loss and gain events. BMC Genomics. 18(1). 684–684. 38 indexed citations
12.
13.
Snijder, Robert, et al.. (2016). A novel standard to evaluate the impact of therapeutic agents on patient safety – The BURDEN OF THERAPY™©∗. Contemporary Clinical Trials Communications. 4. 186–191. 9 indexed citations
14.
Crowther, G. S., C. H. Chilton, Christopher Longshaw, et al.. (2016). Efficacy of vancomycin extended-dosing regimens for treatment of simulatedClostridium difficileinfection within anin vitrohuman gut model. Journal of Antimicrobial Chemotherapy. 71(4). 986–991. 13 indexed citations
15.
Knitsch, Wolfgang, Jean‐Louis Vincent, Stefan Utzolino, et al.. (2015). A Randomized, Placebo-controlled Trial of Preemptive Antifungal Therapy for the Prevention of Invasive Candidiasis Following Gastrointestinal Surgery for Intra-abdominal Infections. Clinical Infectious Diseases. 61(11). 1671–1678. 67 indexed citations
16.
Enoch, David, et al.. (2012). Gram negative bacteraemia – are they preventable and what will E. coli surveillance add?. Journal of Infection Prevention. 14(2). 54–59. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sofie M. van Dorp Breakdown of academic impact, for papers by Kristin Nagaro Breakdown of academic impact, for papers by Ana Álvarez‐Uría Breakdown of academic impact, for papers by Tracey Roberts Breakdown of academic impact, for papers by Linda Ward Breakdown of academic impact, for papers by Rebecca Perlmutter Breakdown of academic impact, for papers by Courtney Jones Breakdown of academic impact, for papers by Paolo Carfagna Breakdown of academic impact, for papers by Minerva Galang Breakdown of academic impact, for papers by Jeanne Couturier
Rankless by CCL
2026